Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study

      Background and Aims

      The effectiveness of vonoprazan relative to that of proton pump inhibitors (PPIs) after gastric endoscopic submucosal dissection (ESD) is unclear. Although previous studies used post-ESD ulcer healing as the outcome measure, post-ESD bleeding rate is the most objective and appropriate outcome measure because it has less ascertainment bias. We aimed to compare the post-ESD bleeding rates between vonoprazan and PPIs.


      This nationwide population-based retrospective cohort study was conducted between 2014 and 2018 and involved 9 hospitals. After 2 days of intravenous PPI administration, either vonoprazan or PPI was administrated from postoperative day 2 to 30.


      Overall, data of 1715 patients (627 patient pairs) were analyzed through propensity score matching. The vonoprazan group had significantly lower post-ESD bleeding rates than the PPI group (overall, 11.9% vs 17.2%, P = .008; bleeding between days 2 and 30, 7.8% vs 11.8%, P = .015). The readmission rate because of post-ESD bleeding was lower in the vonoprazan group (2.4% vs 4.1%, P = .081). Blood transfusion (2.1% vs 3.0%, P = .15) and additional surgery because of delayed perforation (.5% vs 1.0%, P = .32) were not significantly different between the 2 groups. No deaths within 30 days occurred in both groups. On Cox regression analysis, vonoprazan use, lesion location (antrum), aspirin use, direct oral anticoagulant use, and Charlson Comorbidity Index (≥2) were associated with an increased risk of post-ESD bleeding within 30 days.


      Vonoprazan has a lower post-ESD bleeding rate than PPIs. Further prospective studies are required to confirm these results.


      CCI (Charlson Comorbidity Index), CI (confidence interval), ESD (endoscopic submucosal dissection), PSM (propensity score matching), PPI (proton pump inhibitor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Niimi K.
        • Fujishiro M.
        • Goto O.
        • et al.
        Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection.
        Dig Endosc. 2012; 24: 110-116
        • Uedo N.
        • Takeuchi Y.
        • Yamada T.
        • et al.
        Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.
        Am J Gastroenterol. 2007; 102: 1610-1616
        • Kagawa T.
        • Iwamuro M.
        • Ishikawa S.
        • et al.
        Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
        Aliment Pharmacol Ther. 2016; 44: 583-591
        • Martin
        • Zhou Y.
        • Meng C.X.
        • et al.
        Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: a meta-analysis of randomized controlled trials and observational studies.
        Medicine. 2020; 99: e19357
        • Jaruvongvanich V.
        • Poonsombudlert K.
        • Ungprasert P.
        Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis.
        Eur J Gastroenterol Hepatol. 2018; 30: 1416-1421
        • Kang H.
        • Kim B.J.
        • Choi G.
        • et al.
        Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis.
        Medicine. 2019; 98: e15860
        • Jenkins H.
        • Sakurai Y.
        • Nishimura A.
        • et al.
        Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
        Aliment Pharmacol Ther. 2015; 41: 636-648
        • Sakurai Y.
        • Mori Y.
        • Okamoto H.
        • et al.
        Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study.
        Aliment Pharmacol Ther. 2015; 42: 719-730
        • Ichida T.
        • Ueyama S.
        • Eto T.
        • et al.
        Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection.
        Intern Med. 2019; 58: 159-166
        • Liu C.
        • Feng B.C.
        • Zhang Y.
        • et al.
        The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis.
        J Dig Dis. 2019; 20: 503-511
        • Hirai A.
        • Takeuchi T.
        • Takahashi Y.
        • et al.
        Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers.
        Dig Dis Sci. 2018; 63: 974-981
        • Takahashi K.
        • Sato Y.
        • Kohisa J.
        • et al.
        Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers.
        World J Gastrointest Endosc. 2016; 8: 716-722
        • Tsuchiya I.
        • Kato Y.
        • Tanida E.
        • et al.
        Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial.
        Dig Endosc. 2017; 29: 576-583
        • Kim E.H.
        • Park S.W.
        • Nam E.
        • et al.
        Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis.
        Surg Endosc. 2019; 33: 1271-1283
        • Maruoka D.
        • Arai M.
        • Kasamatsu S.
        • et al.
        Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: a propensity score-matching analysis.
        Dig Endosc. 2017; 29: 57-64
        • Ishida T.
        • Dohi O.
        • Yamada S.
        • et al.
        Clinical outcomes of vonoprazan-treated patients after endoscopic submucosal dissection for gastric neoplasms: a prospective multicenter observation study.
        Digestion. 2020; 102: 1-11
        • Ishii Y.
        • Yamada H.
        • Sato T.
        • et al.
        Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial.
        Gastroenterol Res Pract. 2018; 2018: 1615092
        • Horikawa Y.
        • Mizutamari H.
        • Mimori N.
        • et al.
        Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
        Scand J Gastroenterol. 2018; 53: 243-251
        • Yamasaki A.
        • Yoshio T.
        • Muramatsu Y.
        • et al.
        Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection induced ulcers.
        Digestion. 2018; 97: 170-176
        • Hamada K.
        • Uedo N.
        • Tonai Y.
        • et al.
        Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
        J Gastroenterol. 2019; 54: 122-130
        • Hasuike N.
        • Ono H.
        • Boku N.
        • et al.
        A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607).
        Gastric Cancer. 2018; 21: 114-123
        • Chung I.K.
        • Lee J.H.
        • Lee S.H.
        • et al.
        Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study.
        Gastrointest Endosc. 2009; 69: 1228-1235
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Kakushima N.
        • Ono H.
        • Takizawa K.
        • et al.
        Incidence of delayed bleeding among patients continuing antithrombotics during gastric endoscopic submucosal dissection.
        Intern Med. 2019; 58: 2759-2766
        • Oda I.
        • Suzuki H.
        • Nonaka S.
        • et al.
        Complications of gastric endoscopic submucosal dissection.
        Dig Endosc. 2013; 25: 71-78
        • Tsuji Y.
        • Ohata K.
        • Ito T.
        • et al.
        Risk factors for bleeding after endoscopic submucosal dissection for gastric lesions.
        World J Gastroenterol. 2010; 16: 2913-2917
        • Yano T.
        • Hasuike N.
        • Ono H.
        • et al.
        Factors associated with technical difficulty of endoscopic submucosal dissection for early gastric cancer that met the expanded indication criteria: post hoc analysis of a multi-institutional prospective confirmatory trial (JCOG0607).
        Gastric Cancer. 2020; 23: 168-174
        • Toya Y.
        • Endo M.
        • Sugai K.
        • et al.
        Protective effect of proton pump inhibitors and potassium competitive acid blockers against post-gastric endoscopic submucosal dissection bleeding: a single-center, propensity score-matched analysis.
        Scand J Gastroenterol. 2021; 56: 199-204
        • Yoshii S.
        • Yamada T.
        • Yamaguchi S.
        • et al.
        Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents.
        Endosc Int Open. 2020; 8: E481-E487